$ENDV Update on Upcoming Catalysts and Pennant Breakout
$ENDV Upcoming Catalysts:
1. Pre-Clinical Studies To Be Completed in first quarter of 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts
6. Company paying off the rest of its debt with $2.2 million
7. Uplistment to a "National" exchange being considered
8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock
Chart:
There is now a clear pennant forming on the chart, support has held tremendously and the RSI and Fibs have reset to levels corresponding with a second major move up. All marks are checked and it looks ready. Pre-Clinical trials expected in the first quarter of this year.
1. Pre-Clinical Studies To Be Completed in first quarter of 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts
6. Company paying off the rest of its debt with $2.2 million
7. Uplistment to a "National" exchange being considered
8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock
Chart:
There is now a clear pennant forming on the chart, support has held tremendously and the RSI and Fibs have reset to levels corresponding with a second major move up. All marks are checked and it looks ready. Pre-Clinical trials expected in the first quarter of this year.
